Matthew Meriggioli to Middle Aged
This is a "connection" page, showing publications Matthew Meriggioli has written about Middle Aged.
Connection Strength
0.302
-
Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23.
Score: 0.040
-
Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve. 2006 Nov; 34(5):666-9.
Score: 0.026
-
Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006 Apr 25; 66(8):1245-7.
Score: 0.025
-
Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40.
Score: 0.021
-
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
Score: 0.021
-
Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol. 2003 Sep-Oct; 20(5):382-5.
Score: 0.021
-
Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle Nerve. 2003 Feb; 27(2):249-51.
Score: 0.020
-
Clinical immunopharmacology of autoimmune neuropathies and myopathies. Clin Neuropharmacol. 2002 May-Jun; 25(3):174-81.
Score: 0.019
-
Distinguishing clinical and electrodiagnostic features of X-linked bulbospinal neuronopathy. Muscle Nerve. 1999 Dec; 22(12):1693-7.
Score: 0.016
-
Conduction block and continuous motor unit activity in chronic acquired demyelinating polyneuropathy. Muscle Nerve. 1999 Apr; 22(4):532-7.
Score: 0.016
-
Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2019 01; 6(1):e523.
Score: 0.015
-
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052.
Score: 0.015
-
Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. J Hum Genet. 2011 Aug; 56(8):589-94.
Score: 0.009
-
Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006 Feb; 16(2):137-43.
Score: 0.006
-
Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.
Score: 0.006
-
[Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients?]. G Ital Nefrol. 2004 Nov-Dec; 21 Suppl 30:S204-7.
Score: 0.006
-
Monomelic amyotrophy with late progression. Neuromuscul Disord. 2001 Apr; 11(3):305-8.
Score: 0.004
-
Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Minerva Med. 1998 Nov-Dec; 89(11-12):405-9.
Score: 0.004
-
Circulating levels of IGF-I in patients with chronic uremia on conservative dietary treatment. Ren Fail. 1998 Mar; 20(2):357-60.
Score: 0.004
-
Coagulation activation in extracorporeal hemodialysis. Int J Artif Organs. 1997 Mar; 20(3):163-5.
Score: 0.003
-
[Coagulation in hemodialysis]. Minerva Med. 1996 Nov; 87(11):509-14.
Score: 0.003